1. Home
  2. SACH vs ACET Comparison

SACH vs ACET Comparison

Compare SACH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

N/A

Current Price

$1.11

Market Cap

48.6M

Sector

Real Estate

ML Signal

N/A

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

N/A

Current Price

$7.29

Market Cap

69.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SACH
ACET
Founded
2010
1947
Country
United States
United States
Employees
29
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.6M
69.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
SACH
ACET
Price
$1.11
$7.29
Analyst Decision
Hold
Strong Buy
Analyst Count
3
5
Target Price
$2.00
$65.33
AVG Volume (30 Days)
119.3K
140.1K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
18.35%
N/A
EPS Growth
N/A
59.82
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.17
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.80
$0.45
52 Week High
$1.35
$9.05

Technical Indicators

Market Signals
Indicator
SACH
ACET
Relative Strength Index (RSI) 69.13 52.48
Support Level $1.04 $6.54
Resistance Level $1.13 $8.46
Average True Range (ATR) 0.03 0.46
MACD 0.01 -0.01
Stochastic Oscillator 80.51 49.12

Price Performance

Historical Comparison
SACH
ACET

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: